A groundbreaking study has revealed that anthracycline drugs could potentially treat a rare genetic skin disorder by restoring the function of mutated proteins responsible for the condition. The research focuses on Ankyloblepharon-ectodermal dysplasia-cleft lip/palate (AEC) syndrome, a rare genetic disorder characterized by severe skin erosions and developmental abnormalities.
Key Discovery and Mechanism
Scientists identified that two widely used cancer drugs - doxorubicin (Doxo) and epirubicin (Epi) - can effectively restore the function of mutant p63 protein, which causes AEC syndrome when defective. The drugs work by preventing and reversing the abnormal protein aggregation that occurs with mutant p63, thereby restoring its normal cellular functions.
Through high-throughput screening of approximately 700 FDA-approved drugs and 88 epigenetic compounds, researchers found that these anthracyclines could successfully rescue the transcriptional activity of mutant p63 to levels comparable to the normal protein.
Promising Alternative with Reduced Side Effects
A significant breakthrough came with the testing of N,N-dimethyldoxorubicin (diMe-Doxo), a modified version of doxorubicin that shows reduced cardiotoxicity. This variant demonstrated similar effectiveness in disaggregating mutant p63 and restoring its function, while potentially offering a safer therapeutic option.
"The ability of diMe-Doxo to induce p63 disaggregation, despite lacking DNA-damaging activity, indicates that p63 disaggregation may be driven by an independent mechanism, not necessarily linked to the DNA damage response," the researchers noted.
Clinical Implications
The findings represent a significant step forward in developing targeted treatments for AEC syndrome, which currently lacks specific therapeutic options. The research showed that treated cells demonstrated:
- Reduced protein aggregation
- Restored transcriptional activity
- Improved expression of key target genes
- Enhanced skin cell function
Future Directions
While these results are promising, the researchers emphasize the need for further studies to develop variants with reduced toxicity while maintaining therapeutic effectiveness. The team suggests that anthracyclines could serve as a starting point for developing more targeted treatments for AEC syndrome.
The study also highlights the potential of drug repurposing in addressing rare genetic disorders, as it leverages existing approved medications with well-understood safety profiles to potentially accelerate the development of new treatments.
